These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 36333207)
21. Economic evaluation of bivalirudin with provisional glycoprotein IIB/IIIA inhibition versus heparin with routine glycoprotein IIB/IIIA inhibition for percutaneous coronary intervention: results from the REPLACE-2 trial. Cohen DJ; Lincoff AM; Lavelle TA; Chen HL; Bakhai A; Berezin RH; Jackman D; Sarembock IJ; Topol EJ J Am Coll Cardiol; 2004 Nov; 44(9):1792-800. PubMed ID: 15519009 [TBL] [Abstract][Full Text] [Related]
22. Comparison of Bivalirudin Versus Heparin for Maintenance Systemic Anticoagulation During Adult and Pediatric Extracorporeal Membrane Oxygenation. Seelhammer TG; Bohman JK; Schulte PJ; Hanson AC; Aganga DO Crit Care Med; 2021 Sep; 49(9):1481-1492. PubMed ID: 33870916 [TBL] [Abstract][Full Text] [Related]
23. Bivalirudin anticoagulation for left ventricular assist device implantation on an extracorporeal life support system in patients with heparin-induced thrombocytopenia antibodies. Ljajikj E; Zittermann A; Morshuis M; Börgermann J; Ruiz-Cano M; Schoenbrodt M; Gummert J; Koster A Interact Cardiovasc Thorac Surg; 2017 Dec; 25(6):898-904. PubMed ID: 29049666 [TBL] [Abstract][Full Text] [Related]
24. Monitoring bivalirudin therapy in children on extracorporeal circulatory support devices: Thromboelastometry versus routine coagulation testing. Teruya J; Hensch L; Bruzdoski K; Adachi I; Hui SR; Kostousov V Thromb Res; 2020 Feb; 186():54-57. PubMed ID: 31884000 [TBL] [Abstract][Full Text] [Related]
25. Initial conservative management strategy of HeartWare left ventricular assist device thrombosis with intravenous heparin or bivalirudin. Bouzas-Cruz N; Gonzalez-Fernandez O; Ferrera-Durán C; Woods A; Robinson-Smith N; Tovey S; Jungschleger J; Booth K; Shah A; Parry G; MacGowan GA; Schueler S Int J Artif Organs; 2020 Jul; 43(7):444-451. PubMed ID: 31885316 [TBL] [Abstract][Full Text] [Related]
26. Use of bivalirudin for anticoagulation in pediatric extracorporeal membrane oxygenation (ECMO). Kaushik S; Derespina KR; Chandhoke S; Shah DD; Cohen T; Shlomovich M; Medar SS; Peek GJ Perfusion; 2023 Jan; 38(1):58-65. PubMed ID: 34318718 [TBL] [Abstract][Full Text] [Related]
27. Comparison of safety and efficacy of bivalirudin versus unfractionated heparin in percutaneous peripheral intervention: a single-center experience. Sheikh IR; Ahmed SH; Mori N; Gupta A; Mewissen M; Allaqaband S; Bajwa T JACC Cardiovasc Interv; 2009 Sep; 2(9):871-6. PubMed ID: 19778776 [TBL] [Abstract][Full Text] [Related]
28. Mortality, Resource Utilization, and Inpatient Costs Vary Among Pediatric Heart Transplant Indications: A Merged Data Set Analysis From the United Network for Organ Sharing and Pediatric Health Information Systems Databases. Burstein DS; Li Y; Getz KD; Huang YV; Rossano JW; O'Connor MJ; Lin KY; Aplenc R J Card Fail; 2019 Jan; 25(1):27-35. PubMed ID: 30485789 [TBL] [Abstract][Full Text] [Related]
29. Bivalirudin Anticoagulation for a Pediatric Patient with Heparin-Induced Thrombocytopenia and Thrombosis Requiring Cardiopulmonary Bypass for Ventricular Assist Device Placement. Faella KH; Whiting D; Fynn-Thompson F; Matte GS J Extra Corpor Technol; 2016 Mar; 48(1):39-42. PubMed ID: 27134308 [TBL] [Abstract][Full Text] [Related]
30. Evaluation of Bivalirudin As an Alternative to Heparin for Systemic Anticoagulation in Pediatric Extracorporeal Membrane Oxygenation. Hamzah M; Jarden AM; Ezetendu C; Stewart R Pediatr Crit Care Med; 2020 Sep; 21(9):827-834. PubMed ID: 32404633 [TBL] [Abstract][Full Text] [Related]
32. Evaluation of the ventricular assist device programme in the UK. Sharples L; Buxton M; Caine N; Cafferty F; Demiris N; Dyer M; Freeman C Health Technol Assess; 2006 Nov; 10(48):1-119, iii-iv. PubMed ID: 17134596 [TBL] [Abstract][Full Text] [Related]
33. Impact of bivalirudin on outcomes after percutaneous coronary revascularization with drug-eluting stents. Feldman DN; Wong SC; Gade CL; Gidseg DS; Bergman G; Minutello RM Am Heart J; 2007 Oct; 154(4):695-701. PubMed ID: 17892994 [TBL] [Abstract][Full Text] [Related]
34. Bivalirudin May Reduce the Need for Red Blood Cell Transfusion in Pediatric Cardiac Patients on Extracorporeal Membrane Oxygenation. Machado DS; Garvan C; Philip J; Harrington D; Spiess B; Kelly B; Campbell CT; Pelletier JPR; Islam S; Peek GJ; Bleiweis MS ASAIO J; 2021 Jun; 67(6):688-696. PubMed ID: 33031157 [TBL] [Abstract][Full Text] [Related]
35. Economic evaluation of bivalirudin with or without glycoprotein IIb/IIIa inhibition versus heparin with routine glycoprotein IIb/IIIa inhibition for early invasive management of acute coronary syndromes. Pinto DS; Stone GW; Shi C; Dunn ES; Reynolds MR; York M; Walczak J; Berezin RH; Mehran R; McLaurin BT; Cox DA; Ohman EM; Lincoff AM; Cohen DJ; J Am Coll Cardiol; 2008 Nov; 52(22):1758-68. PubMed ID: 19022155 [TBL] [Abstract][Full Text] [Related]
36. Use of bivalirudin as a primary anticoagulant in a child during Berlin Heart EXCOR ventricular assist device support. Medar SS; Hsu DT; Lamour JM; Bansal N; Peek GJ Perfusion; 2020 Mar; 35(2):172-176. PubMed ID: 31223064 [TBL] [Abstract][Full Text] [Related]
37. Economic impact of switching to bivalirudin for a primary percutaneous coronary intervention in a US hospital. Olchanski N; Slawsky KA; Plent S; Kado C; Cyr PL Hosp Pract (1995); 2010 Nov; 38(4):138-46. PubMed ID: 21068538 [TBL] [Abstract][Full Text] [Related]
38. Effect of bivalirudin on aortic valve intervention outcomes study: a two-centre registry study comparing bivalirudin and unfractionated heparin in balloon aortic valvuloplasty. Kini A; Yu J; Cohen MG; Mehran R; Baber U; Sartori S; Vlachojannis GJ; Kovacic JC; Pyo R; O'Neill B; Singh V; Jacobs E; Poludasu S; Moreno P; Kim MC; Krishnan P; Sharma SK; Dangas GD EuroIntervention; 2014 Jul; 10(3):312-9. PubMed ID: 24273237 [TBL] [Abstract][Full Text] [Related]